Showing posts with label Alexza. Show all posts
Showing posts with label Alexza. Show all posts

Thursday, 1 August 2013

Alexza Pharmaceuticals Announces European Launch of ADASUVE® (Staccato® Loxapine)


MOUNTAIN VIEW, Calif., July 30, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (ALXA) today announced that the company's commercial partner Grupo Ferrer Internacional, S.A. has initiated sales of ADASUVE® inhalation powder, pre-dispensed (Staccato® Loxapine) in the European Union ("EU").  ADASUVE is now available in Germany.  The first sale and shipment of product by Ferrer triggers a $1.25 million milestone payment to Alexza, pursuant to the Company's collaboration agreement with Ferrer.

Loxapine (LoxapacLoxitane) is a typical antipsychotic medication, used primarily in the treatment of schizophrenia. It is a member of the dibenzoxazepine class and structurally related to clozapine (which belongs to the chemically akin class ofdibenzodiazepines). Several researchers have argued that Loxapine may behave as an atypical antipsychotic.
Loxapine may be metabolized by N-demethylation to amoxapine, a tetracyclic antidepressant

Schmutz, J.; Kunzle, F.; Hunziker, F.; Gauch, R.; Helv. Chim. Acta 1967, 50, 245.